{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:08:59Z","timestamp":1792674539442,"version":"4.5.0"},"reference-count":67,"publisher":"American Society of Hematology","issue":"10","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,28]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>S\u00e9zary syndrome (SS) is an aggressive leukemic expansion of skin-derived malignant CD4+ T cells. Drug monotherapy often results in disease relapse because of the heterogenous nature of malignant CD4+ T cells, but how therapies can be optimally combined remains unclear because of limitations in understanding the disease pathogenesis. We identified immunologic transitions that interlink mycosis fungoides with SS using single-cell transcriptome analysis in parallel with high-throughput T-cell receptor sequencing. Nascent peripheral CD4+ T cells acquired a distinct profile of transcription factors and trafficking receptors that gave rise to antigenically mature S\u00e9zary cells. The emergence of malignant CD4+ T cells coincided with the accumulation of dysfunctional monocytes with impaired fragment crystallizable \u03b3-dependent phagocytosis, decreased responsiveness to cytokine stimulation, and limited repertoire of intercellular interactions with S\u00e9zary cells. Type I interferon supplementation when combined with a monoclonal antibody targeting the chemokine receptor type 4 (CCR4), unleashed monocyte induced phagocytosis and eradication of S\u00e9zary cells in\u00a0vitro. In turn, coadministration of interferon-\u03b1 with the US Food and Drug Administration\u2013approved anti-CCR4 antibody, mogamulizumab, in patients with SS induced marked depletion of peripheral malignant CD4+ T cells. Importantly, residual CD4+ T cells after S\u00e9zary cell ablation lacked any immunologic shifts. These findings collectively unveil an auxiliary role for augmenting monocytic activity during mogamulizumab therapy in the treatment of SS and underscore the importance of targeted combination therapy in this disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010043","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T17:10:20Z","timestamp":1710522620000},"page":"2384-2397","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Unleashed monocytic engagement in S\u00e9zary syndrome during the combination of anti-CCR4 antibody with type I interferon"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8867-9385","authenticated-orcid":false,"given":"Tony T.","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Cutaneous Lymphoma Program, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9847-7581","authenticated-orcid":false,"given":"Oleg","family":"Kruglov","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cutaneous Lymphoma Program, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-5710","authenticated-orcid":false,"given":"Oleg E.","family":"Akilov","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cutaneous Lymphoma Program, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"issue":"7","key":"2024052418151166800_bib1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"10","key":"2024052418151166800_bib2","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2024052418151166800_bib3","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.clml.2015.02.027","article-title":"Advanced-stage mycosis fungoides and S\u00e9zary syndrome: survival and response to treatment","volume":"15","author":"Alberti-Violetti","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"32","key":"2024052418151166800_bib4","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2024052418151166800_bib5","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"127","author":"Whittaker","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2024052418151166800_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/jid.2014.356","article-title":"CD158k is a reliable marker for diagnosis of S\u00e9zary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells","volume":"135","author":"Moins-Teisserenc","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"16","key":"2024052418151166800_bib7","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/bloodadvances.2018022608","article-title":"Single-cell heterogeneity in S\u00e9zary syndrome","volume":"2","author":"Buus","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"2024052418151166800_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005991","article-title":"Single-cell analysis of S\u00e9zary syndrome reveals novel markers and shifting gene profiles associated with treatment","volume":"7","author":"Borcherding","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2024052418151166800_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12913-021-06109-9","article-title":"Mycosis fungoides and S\u00e9zary syndrome: a population-wide study on prevalence and health care use in Finland in 1998-2016","volume":"21","author":"Keto","year":"2021","journal-title":"BMC Health Serv Res"},{"issue":"spec feature","key":"2024052418151166800_bib10","first-page":"180","article-title":"Opdivo (nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"2024052418151166800_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"2024052418151166800_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncologist"},{"issue":"13","key":"2024052418151166800_bib13","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2024052418151166800_bib14","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024052418151166800_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024052418151166800_bib16","doi-asserted-by":"crossref","first-page":"1738797","DOI":"10.1080\/2162402X.2020.1738797","article-title":"Blockade of programmed cell death protein 1 (PD-1) in S\u00e9zary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation","volume":"9","author":"Saulite","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"2024052418151166800_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jdcr.2019.11.005","article-title":"Pembrolizumab-associated tumor development in a patient with S\u00e9zary syndrome","volume":"6","author":"Malachowski","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"6","key":"2024052418151166800_bib18","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9","key":"2024052418151166800_bib19","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024052418151166800_bib20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2024052418151166800_bib21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.clml.2016.08.019","article-title":"Total skin electron beam therapy in the treatment of mycosis fungoides: a review of conventional and low-dose regimens","volume":"16","author":"Chowdhary","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2024052418151166800_bib22","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1182\/blood-2003-03-0899","article-title":"Bone marrow precursor of extranodal T-cell lymphoma","volume":"102","author":"Gniadecki","year":"2003","journal-title":"Blood"},{"issue":"18","key":"2024052418151166800_bib23","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019002516","article-title":"Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2024052418151166800_bib24","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-18-4099","article-title":"Clonotypic diversity of the T-cell receptor corroborates the immature precursor origin of cutaneous T-cell lymphoma","volume":"25","author":"Hamrouni","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2024052418151166800_bib25","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1101\/gr.121095.111","article-title":"Synthetic spike-in standards for RNA-seq experiments","volume":"21","author":"Jiang","year":"2011","journal-title":"Genome Res"},{"issue":"4","key":"2024052418151166800_bib26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nmeth.3321","article-title":"Quantitative gene profiling of long noncoding RNAs with targeted RNA sequencing","volume":"12","author":"Clark","year":"2015","journal-title":"Nat Methods"},{"key":"2024052418151166800_bib27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fonc.2020.00514","article-title":"New insights into the complex mutational landscape of Sezary syndrome","volume":"10","author":"Mirza","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"2024052418151166800_bib28","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"issue":"24","key":"2024052418151166800_bib29","doi-asserted-by":"crossref","first-page":"39627","DOI":"10.18632\/oncotarget.17383","article-title":"Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sezary syndrome","volume":"8","author":"Izykowska","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"2024052418151166800_bib30","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024052418151166800_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1186\/s12864-018-4772-0","article-title":"Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics","volume":"19","author":"Street","year":"2018","journal-title":"BMC Genomics"},{"issue":"4","key":"2024052418151166800_bib34","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","article-title":"CellPhoneDB: inferring cell\u2013cell communication from combined expression of multi-subunit ligand\u2013receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat Protoc"},{"issue":"1","key":"2024052418151166800_bib35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s42003-020-01625-6","article-title":"Mapping the immune environment in clear cell renal carcinoma by single-cell genomics","volume":"4","author":"Borcherding","year":"2021","journal-title":"Commun Biol"},{"issue":"1","key":"2024052418151166800_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0022-5193(66)90013-0","article-title":"The measurement of diversity in different types of biological collections","volume":"13","author":"Pielou","year":"1966","journal-title":"J Theor Biol"},{"issue":"3","key":"2024052418151166800_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/j.1538-7305.1948.tb01338.x","article-title":"A\u00a0mathematical theory of communication","volume":"27","author":"Shannon","year":"1948","journal-title":"Bell Syst Technol J"},{"issue":"15","key":"2024052418151166800_bib38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0161-5890(97)00130-2","article-title":"A\u00a0Shannon entropy analysis of immunoglobulin and T cell receptor","volume":"34","author":"Stewart","year":"1997","journal-title":"Mol Immunol"},{"issue":"308","key":"2024052418151166800_bib39","doi-asserted-by":"crossref","first-page":"308ra158","DOI":"10.1126\/scitranslmed.aaa9122","article-title":"TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL","volume":"7","author":"Kirsch","year":"2015","journal-title":"Sci Transl Med"},{"key":"2024052418151166800_bib40","article-title":"Deciphering tumor cell evolution in cutaneous T-cell lymphomas: distinct differentiation trajectories in mycosis fungoides and S\u00e9zary syndrome","author":"Jiang","year":"28  2023","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2024052418151166800_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/modpathol.3880265","article-title":"Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall","volume":"14","author":"Yao","year":"2001","journal-title":"Mod Pathol"},{"issue":"6","key":"2024052418151166800_bib42","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1309\/391R-93YF-DB4D-1L35","article-title":"Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias","volume":"113","author":"Lai","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"2024052418151166800_bib43","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood.V76.11.2343.2343","article-title":"Differential expression of CD24-related epitopes in mycosis fungoides\/Sezary syndrome: a potential marker for circulating Sezary cells","volume":"76","author":"Pirruccello","year":"1990","journal-title":"Blood"},{"issue":"5","key":"2024052418151166800_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2024052418151166800_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","article-title":"Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage","volume":"20","author":"Aran","year":"2019","journal-title":"Nat Immunol"},{"issue":"1","key":"2024052418151166800_bib45","doi-asserted-by":"crossref","first-page":"11153","DOI":"10.1038\/ncomms11153","article-title":"CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing","volume":"7","author":"Schneider-Hohendorf","year":"2016","journal-title":"Nat Commun"},{"key":"2024052418151166800_bib46","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.3389\/fimmu.2018.02729","article-title":"TCR repertoire as a novel indicator for immune monitoring and prognosis assessment of patients with cervical cancer","volume":"9","author":"Cui","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"2024052418151166800_bib47","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1084\/jem.20021726","article-title":"Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma","volume":"197","author":"Kari","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"10","key":"2024052418151166800_bib48","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-18-3309","article-title":"Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity associated with disease progression","volume":"25","author":"Borcherding","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2024052418151166800_bib49","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2007-02-071993","article-title":"Killer cell Ig-like receptors CD158a and CD158b display a coactivatory function, involving the c-Jun NH2-terminal protein kinase signaling pathway, when expressed on malignant CD4+ T cells from a patient with Sezary syndrome","volume":"109","author":"Marie-Cardine","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2024052418151166800_bib50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jid.2016.08.016","article-title":"TIGIT and Helios are highly expressed on CD4+ T cells in Sezary syndrome patients","volume":"137","author":"Jariwala","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"8","key":"2024052418151166800_bib51","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1080\/10428194.2018.1564827","article-title":"Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in S\u00e9zary syndrome","volume":"60","author":"Anzengruber","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2024052418151166800_bib52","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1365-2133.2010.09973.x","article-title":"Novel approach to gene expression profiling in Sezary syndrome","volume":"163","author":"Pomerantz","year":"2010","journal-title":"Br J Dermatol"},{"issue":"8","key":"2024052418151166800_bib53","first-page":"874","article-title":"Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sezary's syndrome","volume":"88","author":"Lima","year":"2003","journal-title":"Haematologica"},{"issue":"5","key":"2024052418151166800_bib54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2006.09.012","article-title":"Tribbles homolog 2 inactivates C\/EBP\u03b1 and causes acute myelogenous leukemia","volume":"10","author":"Keeshan","year":"2006","journal-title":"Cancer Cell"},{"issue":"23","key":"2024052418151166800_bib55","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1182\/blood-2009-05-223081","article-title":"BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia","volume":"115","author":"van Galen","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2024052418151166800_bib56","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"2024052418151166800_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nbt.2859","article-title":"The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells","volume":"32","author":"Trapnell","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2024052418151166800_bib57","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/labinvest.3700432","article-title":"UBD, a downstream element of FOXP3, allows the identification of LGALS3, a new marker of human regulatory T cells","volume":"86","author":"Ocklenburg","year":"2006","journal-title":"Lab Invest"},{"issue":"48","key":"2024052418151166800_bib58","doi-asserted-by":"crossref","first-page":"14942","DOI":"10.1073\/pnas.1520393112","article-title":"Imbalanced signal transduction in regulatory T cells expressing the transcription factor FoxP3","volume":"112","author":"Yan","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024052418151166800_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.immuni.2005.01.016","article-title":"Regulatory T cell lineage specification by the forkhead transcription factor foxp3","volume":"22","author":"Fontenot","year":"2005","journal-title":"Immunity"},{"issue":"5609","key":"2024052418151166800_bib60","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"issue":"7","key":"2024052418151166800_bib61","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in S\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2024052418151166800_bib62","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/ijd.15251","article-title":"IFN-\u03b3 reshapes monocyte responsiveness in Sezary syndrome","volume":"60","author":"Torrealba","year":"2021","journal-title":"Int J Dermatol"},{"issue":"16","key":"2024052418151166800_bib63","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood.2020009346","article-title":"Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures","volume":"138","author":"Herrera","year":"2021","journal-title":"Blood"},{"issue":"7731","key":"2024052418151166800_bib64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41586-018-0698-6","article-title":"Single-cell reconstruction of the early maternal\u2013fetal interface in humans","volume":"563","author":"Vento-Tormo","year":"2018","journal-title":"Nature"},{"issue":"24","key":"2024052418151166800_bib65","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","article-title":"FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and Sezary syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2024052418151166800_bib66","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-07-1324","article-title":"Defucosylated anti\u2013CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"13","author":"Yano","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2024052418151166800_bib67","doi-asserted-by":"crossref","first-page":"adv10306","DOI":"10.2340\/actadv.v103.10306","article-title":"Use of pegylated interferon alpha-2a in cutaneous T-cell lymphoma: a retrospective case collection","volume":"103","author":"Gosmann","year":"2023","journal-title":"Acta Derm Venereol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2384\/2226504\/blooda_adv-2023-010043-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2384\/2226504\/blooda_adv-2023-010043-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T18:15:44Z","timestamp":1716574544000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/10\/2384\/515321\/Unleashed-monocytic-engagement-in-Sezary-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010043","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]}}}